Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by SanFrancisco99on Aug 07, 2014 8:42am
477 Views
Post# 22816682

OK Don and Julie: How About An Update????

OK Don and Julie: How About An Update????Zenith and Resverlogix should be called "The Silent Duo" since they both give us so few shareholder updates.  It's been a full SIX MONTHS since we have had a webcast for either or both companies.  That's too long at such a critical time.

I think the need for an update is particularly important with respect to Zenith.  Zenith has all of the IP.  Zenith has all of the formulas except one.  Zenith is where the real growth potential is.  Yet we know almost nothing about what they have.

Since Zenith's formation 14 months ago we have been told almost nothing about what they have and are doing.  

I think we deserve better as shareholders.  

It's past time for us to get an update for both Zenith and RVX.  

Come on, Don and Julie:  We need to hear from you.









Bullboard Posts